Sequential loss of cell cycle checkpoint control contributes to malignant transformation of murine embryonic fibroblasts induced by 20-methylcholanthrene

Journal of Cellular Physiology

Volumn 224, Issue 1, 2010, Pages 49-58

  Mukherjee, Sudeshna ^a   Manna, Sugata ^a   Pal, Debolina ^a   Mukherjee, Pratima ^a   Panda, Chinmay K ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; 5 AZA 2' DEOXYCYTIDINE; CELL CYCLE PROTEIN 20; CHECKPOINT KINASE 1; CYCLIN D1; PROTEIN MAD2; PROTEIN P21; RETINOBLASTOMA PROTEIN; ANTIMETABOLITE; AZACITIDINE; CARCINOGEN; CELL CYCLE PROTEIN; DRUG DERIVATIVE;

ANEUPLOIDY; ANIMAL CELL; ANIMAL EMBRYO; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL POPULATION; CHROMOSOME ABERRATION; DEMETHYLATION; DNA DAMAGE; DOUBLE MINUTE CHROMOSOME; DOWN REGULATION; EMBRYO; FIBROBLAST; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; ROBERTSONIAN CHROMOSOME TRANSLOCATION; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; DNA METHYLATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; GENOTYPE; GESTATIONAL AGE; METABOLISM; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

MURINAE; ROBERTSONIA;

ANEUPLOIDY; ANIMALS; ANTIMETABOLITES; AZACITIDINE; CARCINOGENS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; DNA DAMAGE; DNA METHYLATION; EMBRYO, MAMMALIAN; EPIGENESIS, GENETIC; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; GESTATIONAL AGE; METHYLCHOLANTHRENE; MICE; PHENOTYPE; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 77952505653     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22089     Document Type: Article

References (55)

1. Al Moustafa AE, Foulkes WD, Wong A, Jallal H, Batist G, Yu Q, Herlyn M, Sicinski P, Alaoui-Jamali MA. 2004. CyclinD1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene 23:5252-5256.
2. Alt JR, Cleveland JL, Hannink M, Diehl JA. 2000. Phosphorylation- dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14:3102-3114.
3. Barrett JC, Wiseman RW. 1987. Cellular and molecular mechanisms of multistep carcinogenesis: Relevance to carcinogen risk assessment. Environ Health Perspect 76:65-70.
4. Bartek J, Lukas J. 2001a. Cell cycle. Order from destruction. Science (New York, NY) 294:66-67.
5. Bartek J, Lukas J. 2001b. Mammalian G1- and S-phase checkpoints in response to DNA damage. Current opinion in cell biology 13:738-747. (Pubitemid 33042735)
6. Bartek J, Lukas J. 2001c. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 490:117-122.
7. Bartek J, Lukas J. 2003. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429.
8. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J. 2005. DNA damage response as a candidate anticancer barrier in early human tumorigenesis. Nature 434:864-870.
9. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B. 2000. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev 14:1584-1588. (Pubitemid 30460907)
10. Classon M, Harlow E. 2002. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2:910-917.
11. Collins I, Garrett MD. 2005. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 5:366-373.
12. Cowling VH, Cole MD. 2007. E-cadherin repression contributes to c-Myc-induced epithelial cell transformation. Oncogene 26:3582-3586.
13. Diehl JA, Zindy F, Sherr CJ. 1997. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11:957-972. (Pubitemid 27199876)
14. Durocher D, Jackson SP. 2001. DNA-PK, ATM and ATR as sensors of DNA damage: Variations on a theme? Curr Opin Cell Biol 13:225-231.
15. Egger G, Liang G, Aparicio A, Jones PA. 2004. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463.
16. Endo S, Nettesheim P, Oshimura M, Walker C. 1990. Nonrandom chromosome alterations that correlate with progression to immortality in rat tracheal epithelial cells transformed with N-methyl-N'-nitro-N-nitrosoguanidine. Cancer Res 50:740-747. (Pubitemid 20054208)
17. Ge S, Skaar JR, Pagano M. 2009. APC/C- and Mad2-mediated degradation of Cdc20 during spindle checkpoint activation. Cell Cycle 8:167-171.
18. Giacinti C, Giordano A. 2006. RB and cell cycle progression. Oncogene 25:5220-5227.
19. Gladden AB, Diehl JA. 2005. Location, location, location: The role of cyclin D1 nuclear localization in cancer. J Cell Biochem 96:906-913.
20. Halazonetis TD, Gorgoulis VG, Bartek J. 2008. An oncogene-induced DNA damage model for cancer development. Science (New York, NY) 319:1352-1355.
21. Hoglund P. 2006. DNA damage and tumor surveillance: One trigger for two pathways. Sci STKE 317:pe2.
22. Holmes WF, Soprano DR, Soprano KJ. 2002. Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line. J Biol Chem 277:45408-45419.
23. Hooth MJ, Coleman WB, Presnell SC, Borchert KM, Grisham JW, Smith GJ. 1998. Spontaneous neoplastic transformation of WB-F344 rat liver epithelial cells. Am J Pathol 153:1913-1921. (Pubitemid 28550678)
24. Hritz I, Gyorffy H, Molnar B, Lakatos G, Sipos F, Pregun I, Juhasz M, Pronai L, Schaff Z, Tulassay Z, Herszenyi L. 2009. Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment. Pathol Oncol Res 15:183-192.
25. Ji WD, Chen JK, Lu JC, Wu ZL, Yi F, Feng SM. 2006. Alterations of FHIT gene and P16 gene in nickel transformed human bronchial epithelial cells. Biomed Environ Sci 19:277-284. (Pubitemid 44505565)
26. Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW. 2008. Different mutant/ wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia 10:450-461.
27. Kastan MB, Bartek J. 2004. Cell-cycle checkpoints and cancer. Nature 432:316-323.
28. Kaufmann WK, Levedakou EN, Grady HL, Paules RS, Stein GH. 1995. Attenuation of G2 checkpoint function precedes human cell immortalization. Cancer Res 55:7-11.
29. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, Matsuda K. 2008. CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27:1562-1571.
30. Kiyono T. 2007. Molecular mechanisms of cellular senescence and immortalization of human cells. Expert Opin Ther Targets 11:1623-1637.
31. Klucar J, Al-Rubeai M. 1997. G2 cell cycle arrest and apoptosis are induced in Burkitt's lymphoma cells by the anticancer agent oracin. FEBS Lett 400:127-130.
32. Lee S, Helfman DM. 2004. Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway. J Biol Chem 279:1885-1891.
33. Li GQ, Zhang HF. 2004. Mad2 and p27 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 10:3218-3220. (Pubitemid 39419895)
34. Li Z, Boone D, Hann SR. 2008. Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Proc Natl Acad Sci USA 105: 18794-18799.
35. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
36. Lowry O, Rosenbrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-276.
37. Macaluso M, Montanari M, Cinti C, Giordano A. 2005. Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol 32:452-457.
38. Malumbres M, Barbacid M. 2009. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 9:153-166.
39. Motokura T, Endo K, Kumaki K, Ogata E, Ikeda K. 1995. Neoplastic transformation of normal rat embryo fibroblasts by a mutated p53 and an activated ras oncogene induces parathyroid hormone-related peptide gene expression and causes hypercalcemia in nude mice. J Biol Chem 270:30857-30861. (Pubitemid 126634580)
40. Mukherjee P, Das SK. 1992. Partial characterization, progressive development and correlations of some neoplastic characters in 20-methylcholanthrene-induced transformed murine embryonal fibroblasts. Cancer Lett 67:1-12.
41. Nilsson J, Yekezare M, Minshull J, Pines J. 2008. The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction. Nat Cell Biol 10:1411-1420.
42. Orend G, Hunter T, Ruoslahti E. 1998. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene 16:2575-2583. (Pubitemid 28264035)
43. Porter LA, Donoghue DJ. 2003. Cyclin B1 and CDK1: Nuclear localization and upstream regulators. Prog Cell Cycle Res 5:335-347.
44. Ray D, Terao Y, Nimbalkar D, Hirai H, Osmundson EC, Zou X, Franks R, Christov K, Kiyokawa H. 2007. Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res 67:6605-6611.
45. Rodriguez R, Rubio R, Masip M, Catalina P, Nieto A, de la Cueva T, Arriero M, San Martin N, de la Cueva E, Balomenos D, Menendez P, Garcia-Castro J. 2009. Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells. Neoplasia 11:397-407.
46. Santamaria D, Ortega S. 2006. Cyclins and CDKS in development and cancer: Lessons from genetically modified mice. Front Biosci 11:1164-1188. (Pubitemid 43253468)
47. Shen C, Zhou Y, Zhan J, Reske SN, Buck AK. 2008. Chromosome instability and tumor lethality suppression in carcinogenesis. J Cell Biochem 105:1327-1341.
48. Sotillo R, Hernando E, Diaz-Rodriguez E, Teruya-Feldstein J, Cordon-Cardo C, Lowe SW, Benezra R. 2007. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11:9-23.
49. van Berlo RJ, de Jong B, Oosterhuis JW, Dijkhuizen T, Buist J, Dam A. 1990. Cytogenetic analysis of murine embryo-derived tumors. Cancer Res 50:3416-3421. (Pubitemid 20190153)
50. Vogt N, Lefevre SH, Apiou F, Dutrillaux AM, Cor A, Leuraud P, Poupon MF, Dutrillaux B, Debatisse M, Malfoy B. 2004. Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. Proc Natl Acad Sci USA 101:11368-11373.
51. Williams JP, Stewart T, Li B, Mulloy R, Dimova D, Classon M. 2006. The retinoblastoma protein is required for Ras-induced oncogenic transformation. Mol Cell Biol 26:1170-1182.
52. Woo RA, Poon RY. 2004. Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. Genes Dev 18:1317-1330.
53. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. 2004. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 15:252-256.
54. Zarkowska T, Mittnacht S. 1997. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 272:12738-12746.
55. Zimonjic DB, Zhang H, Shan Z, Factor V, Trent J, Thorgeirsson SS, Popescu NC. 2001. DNA amplification associated with double minutes originating from chromosome 19 in mouse hepatocellular carcinoma. Cytogenet Cell Genet 93:114-116. (Pubitemid 32727558)